Mateo-Vargas María Alejandra, Rodríguez-Pallares Salud, Arca-Suárez Jorge, López-Cerero Lorena, Rodríguez-Iglesias Manuel, Galán-Sánchez Fátima
Departamento de Biomedicina, Biotecnología y Salud Pública, Universidad de Cádiz, Cadiz, Spain.
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña (Spain), A Coruña, Spain.
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0149424. doi: 10.1128/aac.01494-24. Epub 2025 Apr 22.
infections caused by ceftazidime/avibactam-resistant KPC variants are rarely reported. We characterize the evolution of a KPC-8-producing strain involved in a primary infection without previous ceftazidime/avibactam treatment. During a 15-month follow-up, changes in carbapenem susceptibility due to porin alterations were observed, remaining susceptible to meropenem/vaborbactam, imipenem/relebactam, and cefiderocol. High- and low-permeability recombinant isolates analysis revealed that, unlike the widespread ceftazidime/avibactam-resistant variant KPC-31, KPC-8 confers ceftazidime/avibactam resistance without decreasing carbapenemase activity.
由对头孢他啶/阿维巴坦耐药的KPC变体引起的感染鲜有报道。我们对一株产生KPC-8的菌株的进化进行了表征,该菌株参与了未经头孢他啶/阿维巴坦治疗的原发性感染。在15个月的随访期间,观察到由于孔蛋白改变导致碳青霉烯敏感性发生变化,该菌株对美罗培南/巴罗巴坦、亚胺培南/瑞来巴坦和头孢地尔仍然敏感。高渗透性和低渗透性重组分离株分析表明,与广泛存在的对头孢他啶/阿维巴坦耐药的变体KPC-31不同,KPC-8赋予头孢他啶/阿维巴坦耐药性,而不会降低碳青霉烯酶活性。